Werewolf Therapeutics (NASDAQ:HOWL) Releases Earnings Results, Beats Estimates By $0.03 EPS

Werewolf Therapeutics (NASDAQ:HOWL) issued its quarterly earnings results on Thursday. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.41) by $0.03, reports. Werewolf Therapeutics had a negative net margin of 578.80% and a negative return on equity of 48.25%.

Werewolf Therapeutics Stock Performance

NASDAQ:HOWL opened at $2.30 on Friday. The company has a market capitalization of $100.51 million, a P/E ratio of -1.67 and a beta of 0.41. The business has a fifty day simple moving average of $2.27 and a two-hundred day simple moving average of $3.02. The company has a debt-to-equity ratio of 0.24, a current ratio of 12.13 and a quick ratio of 12.13. Werewolf Therapeutics has a 1 year low of $1.66 and a 1 year high of $8.19.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in HOWL. American Century Companies Inc. raised its stake in Werewolf Therapeutics by 50.7% in the 2nd quarter. American Century Companies Inc. now owns 37,634 shares of the company’s stock valued at $92,000 after acquiring an additional 12,656 shares during the period. SG Americas Securities LLC purchased a new position in shares of Werewolf Therapeutics in the third quarter worth about $29,000. Point72 DIFC Ltd bought a new stake in shares of Werewolf Therapeutics in the second quarter valued at approximately $34,000. Rhumbline Advisers purchased a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at approximately $79,000. Finally, Acadian Asset Management LLC boosted its holdings in Werewolf Therapeutics by 22.8% in the 2nd quarter. Acadian Asset Management LLC now owns 212,296 shares of the company’s stock worth $516,000 after buying an additional 39,413 shares during the period. Institutional investors own 64.84% of the company’s stock.

Werewolf Therapeutics Company Profile

Werewolf Therapeutics, Inc, a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies.